25P-NBOMe

25P-NBOMe2DACS

25P-NBOMe, also known as 2C-P-NBOMe, is a synthetic psychedelic compound that belongs to the NBOMe series of psychoactive drugs. This chemical is closely related to other compounds in the NBOMe series, which are derived from the phenethylamine class of psychoactive substances, originally popularized by chemist Alexander Shulgin. 25P-NBOMe acts primarily as an agonist for the 5-HT2A receptor, which is thought to be responsible for its psychedelic effects. The compound has been studied to a limited extent and is known for its potent and selective activation of the 5-HT2A receptor, leading to its investigation for various scientific and potentially therapeutic applications. However, like other substances in the NBOMe series, 25P-NBOMe has been associated with a number of adverse effects and poses significant risks due to its high potency and the narrow margin between recreational and potentially harmful doses.

Chemistry

25P-NBOMe is a derivative of the phenethylamine psychedelic 2C-P, itself a member of the 2C family of psychedelics that were first synthesized by Alexander Shulgin. The NBOMe addition refers to the N-benzyl methoxy group that is attached to the nitrogen of the phenethylamine backbone, significantly altering its pharmacological profile. This modification increases the affinity and selectivity of 25P-NBOMe for the 5-HT2A receptor, making it much more potent than its 2C counterparts.

Pharmacology

The primary mechanism of action of 25P-NBOMe involves its function as an agonist at the 5-HT2A receptor, a subtype of the serotonin receptor. This action is believed to be central to the psychedelic effects of the compound. The exact pharmacological profile, including its selectivity and affinity for other receptor sites, remains under-researched. However, the potency of 25P-NBOMe and other NBOMe compounds at the 5-HT2A receptor is well-documented, with effects that can be many times stronger than those of other classical psychedelics.

Effects

The effects of 25P-NBOMe can vary widely and are dose-dependent, with higher doses increasing the risk of negative outcomes. Users have reported a range of psychedelic experiences, including enhanced visual and auditory perceptions, altered sense of time, euphoria, and introspection. However, the compound has also been associated with negative effects such as anxiety, confusion, hypertension, and severe vasoconstriction. Due to its potency, there is a significant risk of overdose, which can lead to more severe health issues, including seizures, cardiac arrest, and death.

Legal Status

The legal status of 25P-NBOMe varies by country, but it has been banned or controlled in several jurisdictions due to concerns over its safety and potential for abuse. In some countries, it is classified alongside other NBOMe compounds as a controlled substance, making its manufacture, distribution, and possession illegal.

Safety and Risks

Due to its high potency and the narrow therapeutic index, 25P-NBOMe is considered to be a substance with a high risk of overdose and adverse effects. The variability in individual responses and the potential for misrepresentation as other, less potent psychedelics further increase the risks associated with its use. There have been reports of hospitalizations and fatalities linked to the consumption of 25P-NBOMe, highlighting the dangers of experimenting with this and similar research chemicals.

This substance-related article is a stub. You can help WikiMD by expanding it.